|
|
|
|
Vol. 53, Issue 6, 991-998, June 1998
Faculties of Pharmacy (I.G., N.Z., J.P.U.) and
Medicine (J.P.U.),
University of Toronto, Ontario, Canada, and
Department of Psychiatry
(D.M.), Faculty of Health Sciences, McMaster University, Hamilton,
Ontario, Canada
Olanzapine was shown to be oxidized to a reactive intermediate by HOCl,
which is the major oxidant produced by activated neutrophils. A mass
spectrum obtained using a flow system in which the reactants were fed
into a mixing chamber and the products flowed directly into a mass
spectrometer revealed a reactive intermediate at
m/z 311. This is 2 mass units less than
the protonated molecular ion of parent olanzapine and suggests that the
reactive intermediate is a nitrenium ion. The reactive intermediate
could be trapped with glutathione or N-acetylcysteine to
produce two conjugates. These data are analogous to results we reported
previously with the structurally related atypical antipsychotic agent
clozapine. However, the clozapine and olanzapine reactive metabolites
showed differences in their ability to cause toxicity to human
neutrophils. Toxicity to neutrophils was observed only at high
concentrations of clozapine (>50 µM) when HOCl was used
to generate reactive metabolite. In contrast, concentration-dependent
toxicity (p < 0.05) was observed when
neutrophils were incubated with clozapine (0-20 µM) and
H2O2 to generate clozapine reactive metabolite. No toxicity was observed with clozapine alone (at concentrations of > 50 µM). Similar results were observed in
monocytes and HL-60 cells. Olanzapine reactive metabolite only seemed
to cause slight toxicity at the highest concentrations tested (20 µM), even when the reactive metabolite was generated
using H2O2. Neutrophils from two patients with
a history of clozapine-induced agranulocytosis seemed to be more
sensitive to the toxic effects of the clozapine reactive metabolite;
however, the numbers are too small to draw any definite conclusions.
This article has been cited by other articles:
![]() |
P. HeiSer, F. Enning, J.-C. Krieg, and H. Vedder Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro J Psychopharmacol, November 1, 2007; 21(8): 851 - 856. [Abstract] [PDF] |
||||
![]() |
D. P. Williams, M. Pirmohamed, D. J. Naisbitt, J. P. Uetrecht, and B. K. Park Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine Mol. Pharmacol., July 1, 2000; 58(1): 207 - 216. [Abstract] [Full Text] |
||||
![]() |
W. G. Lai, I. Gardner, N. Zahid, and J. P. Uetrecht Bioactivation and Covalent Binding of Hydroxyfluperlapine in Human Neutrophils: Implications for Fluperlapine-Induced Agranulocytosis Drug Metab. Dispos., March 1, 2000; 28(3): 255 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Reilly, R. D. MacArthur, M. J. Farrough, L. R. Crane, P. M. Woster, and C. K. Svensson Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals? J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1356 - 1364. [Abstract] [Full Text] |
||||
![]() |
I. Gardner, J. S. Leeder, T. Chin, N. Zahid, and J. P. Uetrecht A Comparison of the Covalent Binding of Clozapine and Olanzapine to Human Neutrophils In Vitro and In Vivo Mol. Pharmacol., June 1, 1998; 53(6): 999 - 1008. [Abstract] [Full Text] |
||||